BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. BRAF, G-protein-coupled receptor binding, HIV infection, Hypothalamus, Vitamin E)
Bookmark Forward

QuickView for JNJ-26481585 (compound)


Genetic Markers

Most Correlated Genes

  1. CRIP1
  2. TPSB2
  3. POSTN
  4. ANO1
  5. COL11A1
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. organic cyclic compound binding
  2. heterocyclic compound binding
  3. nucleoplasm
  4. organic cyclic compound metabolic process
  5. vesicle
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
  2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
  3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathw…
  2. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
  3. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial…
  4. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhab…
  5. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on my…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Le…
  2. A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Ly…
  3. A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination Wit…
  4. A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Pre…
  5. A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.